Kava is everywhere… but is it silently damaging your patients’ livers?

Kava is now turning up in Australian pharmacies, health food stores and online — marketed as a “natural” fix for anxiety, stress and insomnia.

But behind the glossy labels lies a messy reality: wild dosing, limited clinical trials, and real-world reports of hepatotoxicity, drug interactions and impaired driving.

In this episode of Cracking Addiction, addiction medicine specialist Dr Ferghal Armstrong breaks down what most clinicians don’t know about kava — and what you need to start asking your patients today.

You’ll discover how a traditional Pacific Island ceremonial drink became a CNS depressant supplement with:

Huge dose discrepancies between traditional use (up to 8000 mg kavalactones) and commercial capsulesUnclear safety margins and a weak evidence base dominated by descriptive and traditional-use reports

Short- and long-term effects: muscle relaxation, drowsiness, dermatopathy, weight loss, GI disturbance, impotence and poor overall health

Serious drug interactions with benzodiazepines, alcohol, barbiturates, levodopa, anticonvulsants, MAOIs, antipsychotics and anticoagulants

Driving impairment data from real motor vehicle collisions in kava-using populations

Red-flag groups: young people, pregnant or breastfeeding women, and those with harmful use patterns

If you’re a GP, pharmacist, nurse, psychiatrist or allied health professional, this episode will help you:

Ask targeted questions about kava use in your consultations

Screen for concurrent CNS depressants and liver disease

Give clear, practical advice on driving, alcohol and daily functioning

Counsel patients with nuance instead of either fear or blind reassurance

You’ll walk away with a sharper lens on “natural” supplements, a better grasp of kava safety, and a framework to protect your patients from avoidable harm.

👉 Watch now to learn why kava is not a benign supplement — and what to do about it.

Don’t forget to like, subscribe, and share this episode with colleagues who are seeing more kava in their clinics.